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ABSTRACT 
 
Adoptive cellular immunotherapy (ACT) refers to the process of transferring immune cells 
(autologous or allogeneic) directly to the host as a treatment for cancer or infectious diseases. 
The effector cells could be antigen-specific, like T cells, or non-specific, such as NK cells or 
lymphokine-activated killer (LAK) cells. A substantial amount of evidence shows that T cells 
play an important role in controlling pathogens and tumor growth. Controlling pathogens and 
orchestrating the function of immune cells depends on engagement of the nominal TCR (T-
cell receptor) with its ligand (the MHC class I or -II peptide complex), the structure and 
function of T cell receptor (TCR) and the subsequent immune effector functions upon TCR 
triggering (cytotoxicity, proliferation, cytokine production).  
 
Tumor-infiltrating T-cells (TILs) represent a source of T-cells for the immunotherapy of 
patients with tumors of the central nervous system and pancreas. According to the results of 
paper I and II, we successfully established a rapid TIL expansion protocol for patients with 
brain tumors or pancreatic cancer. TILs were shown to produce Th1-cytokines and were able 
to recognize autologous tumor cells defined by cytokine production or cytoxicity. 
 
In paper III, we found that tumor associated antigens (TAAs)-reactive T-cells could be 
successfully expanded from patients with glioma with IL-2, IL-15 and IL-21; they exhibit a 
Th1 cytokine pattern and a central memory phenotype. NY-ESO-1 expression was found in 
15/38 cases and survivin expression in 20/40 cases in glioblastoma, defined by immunohisto-
chemistry. Thus, NY-ESO-1 or survivin represent a potential target for anti-NY-ESO-1 or 
anti-survivin directed T-cells for the biological therapy of patients with glioblastoma (GBM). 
 
Mesothelin was first identified to be overexpressed in ovarian cancer. It is constitutively 
expressed in normal tissue, e.g. pericardium, pleura or peritoneum. This 40kDa protein could 
serve as a tumor marker and as a target of immunotherapy for anti-cancer directed T-cells. In 
paper IV, mesothelin was found to be expressed in 4 out of 11 GBM tissues, by immune-
fluorescence staining. Mesothelin directed T cell reactions were also observed in a whole 
blood assay (WBA) measured in 293 patients with brain tumors. Mesothelin immunogenic 
epitopes were also identified using a peptide mapping assay; mesothelin-specific TILs could 
be expanded from glioma samples. 
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We analyzed in detail potential prospective factors in patients with GBM (n=145) and non-
GBM (n=60) which refers to glioma (WHO grade II or III). In paper V, we performed 
univariate Kaplan-Meier (K-M) survival analysis by setting of groups based on demographic, 
clinical, immunological parameters and immunological reactivity patterns, then we defined 
factor(s) with a cut-off strategy. We performed further multivariate analysis with a Cox 
proportional hazards model (forward and backward stepwise analysis) to determine the key 
factor related with patient’s survival by considering (and omitting) interactions between 
employed factors. We found that T-cell reactivity to an individual survivin epitope (97-111) 
is positively related (P=0.024) with survival of patients with GBM. The same was found to be 
true for the serum cytokine pattern of IL-4/IL-5/IL-6 (P=0.052) and IFN-γ/TNF-α/IL-17A 
(P=0.003) which could serve as ‘predictor’ for prognosis in clinical settings. The cytokine 
serum profile as well as the immune reactivity to survivin may serve as a clinically relevant 
indicator for the clinical follow up of patients with GBM after surgery and provide a viable 
option to offer tailored immunological therapy. 
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1 INTRODUCTION 
 
‘Self-recognition and non-self-elimination’ is the function of immune system which refers to 
the multi-faced interplay of different parts of the immune system on the levels of organs, cells 
and molecules. Throughout the body, two groups of immune organs are defined: ‘primary’ or 
‘central’; the first including the thymus and bone marrow, where immune cells have been 
generated. The latter refers to the ‘secondary’ or ‘peripheral’ immune system, which 
encompasses: lymph nodes, appendix, Peyer's patches, tonsils, adenoids, spleen and Mucosal-
associated lymphoid tissue (MALT). Immune molecules, such as cytokines or defensins are 
mainly produced by immune cells and act as nodes in the formation of immune networks. 
From the aspect of evolution and specificity, the immune system could be classified into two 
systems: the innate immunity, also called natural immunity, refers to the function of cells or 
proteins which are consistently present and allow an immune response to pathogens without a 
refractory period; the reactions of innate immunity peak within 12 hours after engagement; 
long term protection is not provided. Epithelial barriers, phagocytes, dendritic cells, NK cells 
and complement are important constituent parts of this system [1]. After 12 hours, adaptive 
immune response or ‘acquired immunity’ will continue to eliminate pathogens which could 
overcome innate immune defenses in the first place. B- or T- lymphocytes are responsible for 
the antigen specific reactions during period of adaptive immunity, they constitute humoral 
immunity and cell-based immunity, respectively. Immunological memory is also formed in 
this duration to form long term protection [2]. 
 
The immune system may be categorized into three areas: i). immunosurveillance, ii). 
immuno-homeostasis, iii). immuno-defense. Immuno-defense refers to the recognition of 
microbes as ‘foreign’ followed by successful elimination of the foreign microbes. The 
capability of immune system in maintaining stability of the inner micro-environment is called 
immuno-homeostasis [1]: the immune system could recognize and remove  dead or damaged 
cells. Recognition and elimination of transformed cells by immune system is called immune-
surveillance [2]. Tumor immunogenicity establishment by the host immune system is actually 
a balance between cancer immune responses and tumorogenesis [3], the active interplay of 
transformed cells and host immune cells. 
 
Glioma arises from glia cells in the central nervous system (CNS) [4]. There are four glioma 
grades according to the WHO classification system, which can be classified as low (Grade I 
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and II) and high (Grade III and IV) grade groups. Within the low grade group, grade I glioma 
is histologically benign with a low potential for malignant progression, while grade II is 
associated with an increased risk to high grade progression. Grade III and IV gliomas are 
defined as malignant brain tumors. Grade IV glioma represents glioblastoma multiforme 
(GBM), an aggressive brain tumor with poor prognosis and a medium survival of 14.6 
months, a survival value which did not change significantly during the last 20 years [5]. 
 
Pancreatic cancer, especially pancreatic ductal adenocarcinoma, is often associated with late 
diagnosis, frequent metastasis, resistance to chemotherapy and radiation therapy, and a poor 
prognosis which did not significantly change for the last decades. The 5-year survival rate of 
PDA is as low as 1%–4% and the median survival of patients with unresectable tumor is 
around 4-6 months [6]. 
 
This thesis will focus on tumor specific T cells which could be expanded from tumor (glioma 
or pancreatic cancer) tissue or from the patients’ peripheral blood mononuclear cells 
(PBMCs) for potential clinical immunotherapy. Tumor infiltrating lymphocytes (TILs) are 
derived from fresh brain tumor tissue and could be expanded to meet the requirement for 
clinical therapy. TILs are often tumor specific and functional in elimination of tumor cells; a 
perfect candidate for adoptive cellular immunotherapy (ACT) targeting tumor mutations.  
 
In this thesis, we define NY-ESO-1，Survivin and Mesothelin as TAAs and also as potential 
targets for cellular therapy. NY-ESO-1 was identified in 1997 by Chen et al with a SEREX 
technique, screening a tumor cDNA library with sera from cancer patients [7]. NY-ESO-1, 
‘NY’ refers to New York, ‘ESO’ stands for esophageal carcinoma, ‘1’ means firstly 
identified as a new gene family, also named as cancer/testis antigen 1B (CTAG1B) or the L 
antigen family member 2 (LAGE-2), which is broadly expressed in many kinds of cancers 
(around 30-40% tumors) and shows a high degree of immunogenicity. Survivin, (baculoviral 
inhibitor of apoptosis repeat-containing 5, BIRC5) has a central role in apoptosis, cell cycle, 
e.g. and according to its name, it plays a critical role in tumor cell apoptosis inhibition and 
tumor survival. Survivin could serve as a potential target for cancer therapy, some of the 
peptides derived from survivin are highly immunogenic [8, 9]. Mesothelin, encoded by the 
MSLN gene, is overexpressed mainly in pancreatic adenocarcinoma (~100%), ovarian cancer 
(70%), lung adenocarcinoma (50%) or mesothelioma (~100%) as a tumor differentiation 
antigen [10]. It is derived from a 71kDa protein which anchors to the cell surface with 
glycophosphatidylinositol (GPI) and contains a shed protein (31kDa) called megakaryocyte 
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potentiating factor (MPF). In certain conditions, the mesothelin protein is shed and detectable 
in serum. Mesothelin can be recognized as a target for immunotherapy due to its limited 
expression in normal tissue and high expression in tumor lesions. 
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1.1 TUMOR BIOLOGY OF GLIOMA 
1.1.1 Tumor classification and genetic/molecular features 
 
Among all primary brain tumors, glioma account for around 26% of tumors located in the 
central nervous system. [11]. Based on the 2007 World Health Organization (WHO) 
classification system (2007 CNS WHO), pathological characteristics, which are commonly 
used in brain tumor grading system include: atypical cells, proliferation, mitosis and necrosis. 
Gliomas without any of these pathological changes are classified as ‘grade I’ which mainly 
occurs in the pediatric population with a low potential of malignant progression. Certain brain 
tumors like ganglioglioma, dysembryoplastic neuro-epithelial tumor (DNET), pilocytic 
astrocytoma (PA) and pleomorphic xanthoastrocytoma (PXA) belong to this group [12]. With 
only one of the characteristics, grade II gliomas could be histologically divided into 3 
subtypes due to their origin: astrocytoma, oligodendroglioma and oligoastrocytoma. The 
prognosis of grade II astrocytoma is significantly poorer than oligodendroglioma with a 
median overall survival (5.6 years versus 11.6 years) and an increased risk of progression to 
high grade glioma progression (75% versus 45%) [13]. A frequent driver mutation within all 
3 subtypes is isocitrate dehydrogenase (IDH) R132 which can induce the generation of 2-
hydroxyglutarate (2-HG) that plays a role in tumorigenesis [14]. Beside the IDH mutation, 
co-mutations in different histological subtypes such as 1p/19q deletion, the capicua 
transcriptional repressor (CIC) mutation and FUSE binding protein1 (FUBP1) mutations in 
oligodendroglioma, or the TP53 loss/mutation and X-linked alpha thalassemia /mental 
retardation syndrome (ATRX)  in astrocytoma effect the clinical outcome [15]. 
 
Anaplastic (WHO grade III) gliomas with 3 subtypes (anaplastic astrocytoma/oligodendro-
glioma /oligoastrocytoma) could be either primary, without any history of low grade gliomas 
or secondary to progression of low grade gliomas. Similar to grade II gliomas, the difference 
in histology is associated with a different 5 year survival (26% in anaplastic astrocytoma 
versus 50% in anaplastic oligodendroglioma) and an increased risk to GBM progression. 
Besides the mutation profile histology, grade III gliomas contain more specific co-mutations. 
For instance, the loss of phosphatase and tensin homolog (PTEN), retinoblastoma 1 (RB1) 
loss, cyclin-dependent kinase (CDKN2A) loss and cyclin dependent 4 or 6 (CDK4/6) 
amplification could be found in anaplastic astrocytoma (1.7% of primary brain tumor) while 
phosphatase and tensin homolog (PTEN) loss, cyclin-dependent kinase (CDKN2A) loss and 
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telomerase reverse transcriptase (TERT) promotor mutation could be found in anaplastic 
oligodendroglioma (0.6% of primary brain tumors) [15-17]. 
 
 
 
Figure 1. Driver events in adult gliomagenesis. RTK, receptor tyrosine kinase; PI3K, phosphoinositide 3-kinase; 
EGFR, epidermal growth factor receptor; NF1, neurofibromin 1. Source: DeVita, Hellman, and Rosenberg's 
Cancer: Principles & Practice of Oncology, 10edition. (2015). Section 10. Neoplasms of the Central Nervous 
System:96. Molecular Biology of Central Nervous System Tumors:1403-1410. 
 
Different from the 2007 CNS WHO, an updated version (rather than a formal new edition), 
has been summarized in May 2016 with major changes concerning tumor classification: 
Molecular genetic features and histology parameters have been combined to generate a higher 
diagnostic accuracy. Beside the traditional light microscope features, newly genotypic 
parameters include IDH wild-type/mutation, 1p/19q co-deletion, TP53 mutation and ATRX 
loss, which serves as a key or ‘driver mutation’ in diffuse or anaplastic astrocytoma or 
oligodendrglioma, and even GBM. It should be noted that the diagnosis of oligoastrocytoma 
or anaplastic oligoastrocytoma according to the 2007 CNS WHO, which was difficult to 
define objectively, and caused high interobserver discordance, does no longer exist. With the 
new criteria, most of the oligoastrocytoma cases could be classified as either astrocytoma or 
oligodendroglioma, the rare and true oligoastrocytoma cases are categorized in the ‘not 
otherwise specified (NOS)’ group. A similar strategy could be followed for anaplastic 
oligoastrocytoma [18]. 
 
As the most common malignant brain tumor, glioblastoma (WHO grade IV), which accounts  
TP53 pathway dysregulation(TP53 loss/mutation, CDKN2A deletion, MDM1/2/4 amplification)
RB pathway dysregulation(RB1 loss, CDKN2A deletion, CDK4/6 amplification) 
RTK/RAS/PI3K signaling dysregulation(EGFR amplification/mutation, PTEN loss/mutation, PI3K mutation, NF1 loss 
TERT promoter mutation 
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for around 16% of all primary brain tumors and around 60% of gliomas [19], can be 
classified into 3 groups according to 2007 CNS WHO: IDH-wildtype glioblastoma, IDH-
mutant glioblastoma  and glioblastoma NOS. IDH-wildtype glioblastoma is the synonym of 
primary glioblastoma which refers to the tumorigenesis from a de novo pathway, without 
evidence of a precursor lesion. Tumors which occur through progression of low grade 
gliomas are named as ‘secondary’ or ‘IDH-mutant glioblastoma’. Differences in key 
characteristics such as age, tumor incidence, mutation profiles and patient survival are shown 
in Table 1 [18]. 
 
The adult glioma formation from low grade to high grade is provided in Figure 1 according 
to the database of The Cancer Genome Atlas (TCGA) project. 
1.1.2 Hallmarks of glioma 
 
Hallmarks of cancer were well-defined by Hananhan and Weinberg in 2011 in a Cell review 
which provided the framework for understanding the biological capabilities of neoplastic 
diseases and breakthrough points for cancer treatment [20]. Genomic instability and mutation 
as a hallmark is now a well accepted concept in oncology and /or in onco-immunology. 
 
 
Table  1. Characteristics of IDH-wildtype/mutant glioblastomas. Source: The 2016 World Health Organization 
Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol (2016) 131:803–820. 
IDH‐wildtype GBM IDH‐mutant GBM
Synonym Primary GBM, IDH‐wildtype Secondary GBM, IDH‐mutant
Proportion of GBMs ~90% ~10%
Median age at diagnosis ~62 years ~44 years
Male‐to‐female ratio 1.42:1 1.05:1
Mean length of clinical history 4 months 15 months
Median overall survival
 ‐Surgery+radiotherapy 9.9 months 24 months
 ‐Surgery+radiotherapy+chemotherapy 15 months 31 months
Location Supratentorial Preferentially frontal
Necrosis Extensive Limited
TERT promoter mutations 72% 26%
TP53 mutations 27% 81%
ATRX mutations Exceptional  71%
EGFR amplification 35% Exceptional
PTEN mutations 24% Exceptional
Precursor lesion Not identifiable; develops 
de novo
Diffuse astrocytoma 
Anaplastic astrocytoma
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1.1.2.1 Cancer stem cells (CSCs) 
 
Cancer stem cells (CSCs) refer to the ability of self-renewal, they act similar as compared to 
hemotopoietic stem cells, yet they exhibit malignant biological behavior. The role of CSCs is 
increasingly accepted in gliomas, especially in GBM initiation, progression, angiogenesis; it 
has also biological meaning for treatment (i.e. radiotherapy or chemotherapy) resistance [21]. 
Although the existence of CSCs is well accepted, the challenge remains how to distinguish 
CSCs from ‘normal CNS stem cells’ or common cancer cells, defined by morphological 
aspects or by genetic/molecular fingerprints [22]. Some shared markers like CD133 
(Prominin-1), oligodendrocyte lineage transcription factor 2 (OLIG2), inhibitor of 
differentiation protein (ID1) or Nestin could be aid to identify CSCs. A list of well accepted 
optional markers, which could be used in CSCs identification, either by flow cytometry or by 
detection on the gene/protein level includes: CD133, CD44+ID1, stage-specific embryonic 
antigen-1(SSEA-1)/Lewis X/CD15, neuronal cell adhesion molecule L1CAM/CD171, 
Integrin α6 or A2B5(ganglioside marker) [22, 23]. CD133, the first and most predominant 
marker for glioma CSCs, is a penta-span transmembrane glycoprotein encoded by the 
PROM1 gene, with its function in proliferation and differentiation. Since the mRNA level of 
CD133 is not directly related with ‘stemness’, so other components served as marker, e.g. the 
glycosylated form of CD133 [24]; however, some CSCs could still be CD133 negative [25]. 
Equipped with a sensor to monitor subtle changes within the CNS environment, CSCs are 
able to self-regulate via intrinsic and extrinsic mechanisms [22]. Intrinsic factors refer to 
genetic and epigenetic mechanism, metabolism regulation; while extrinsic factors refer to 
niche factors (signal pathways activated by environment molecules and receptors), immune 
modulation and the formation of ‘tumor microenvironment’.  
1.1.2.2 Tumor Heterogeneity 
 
Similar to human society and other organism communities, the ‘diversity’ of individuals 
within the population could contribute to the stability, facing a changeable and diverse 
environment. This kind of diversity is of significance for the whole population. Similarly, the 
diversity of tumor cells is reflected in their profile and biological behavior, such as 
morphology, proliferation ratio, invasion ability, metastatic capabilities and treatment 
resistance. The intuitive clue of GBM morphological features could be observed through the 
light microscope: atypical cellular structures with nuclear polymorphisms, co-existence of 
heterogeneous cell populations. The pathologist use the word ’multiforme’ to describe the 
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high cellular nonuniformity [26]. There are a plenty of examples for molecular heterogeneity 
in glioma: a). Remarkable differences among cells from the same tumor lesion or established 
tumor cell line [27]. b). Chromosomal aberration disparity among different areas of the same 
tumor [28]. c). Expression of EGFRvIII is limited to certain subgroups of tumor cells, rare 
cases with broad EGFRvIII expression [29]. d). Uneven distribution and expression of O6-
methylguanine–DNA methyltransferase (MGMT) within one GBM tumor lesion [30]. The 
origin of heterogeneity in glioma, can be exploited by alternative models: (1). Clonal 
evolution: even though with monoclonal initiation, mutations accumulated during tumor 
progression would induce the state of genetic chaos, ‘tough’ clones who could survive under 
selective pressure such as hypoxia, chemo-therapy or radiotherapy will give rise to a 
heterogeneous population [31]. (2). CSCs model: under selective pressure as a driving force, 
CSCs would be altered to adapt to the changeable intrinsic or extrinsic environment. At the 
same time; CSCs never stop to give rise to progeny during the progression, a series of 
daughter cells with distinctive biological fingerprint will be the basis of heterogeneity [32]. 
(3). Cell plasticity: epigenetic regulation could induce tumor cells with the same initiation 
into different behavior and capacity, like drug resistance. (4). Cell-to-cell interaction: cross 
talk between tumor cells via physical contact or network established functional molecules 
could enhance the survival of the whole tumor population, which would cause retained tumor 
diversity [33]. 
1.1.2.3 Angiogenesis, invasion and metastasis 
 
An ‘angiogenetic switch’ is activated and remains ‘on’ during the process of glioma-genesis 
in order to enhance delivery of nutrients or tumor cell migration. The glioma vascular 
structure is remarkably disorganized due to angiogenesis, which would cause further hypoxia, 
heterogeneity and drug resistance. The formation of a vascular niche with CSCs could give 
rise to other tumor lesion [34]. However, this could also be seen as a therapeutic target. ‘The 
angiogenetic switch’ is controlled by key regulators such as signaling proteins, oncogene 
expression or inflammatory cytokines derived from immune cells (Figure 2). Vascular 
endothelial growth factor (VEGF) has been well described and is a well characterized 
signaling protein and angiogenesis inducer, whose expression is tightly related with hypoxia 
and acidosis. By binding with its receptors (VEGFR-1-3), VEGF could orchestrate the 
epithelial proliferation and migration via the hypoxia inducible factor 1(HIF-1)/VEGF-A 
pathway, and induce increased permeability of vasculature structure which could cause 
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Figure 2.  Angiogenetic switch.  Source: The 
scientific contributions of M. Judah Folkman to 
cancer research. Nature Reviews Cancer 8, 647-654. 
elevated interstitial pressure and edema [35]. Additionally, interleukin-8 (IL-8) from 
microglia cells could partly be responsible for hypoxia condition [36]. 
 
Unlike other kind of malignant solid tumors, glioma metastasizes through extracellular routes, 
mainly instead of the intravascular or 
lymphatic system. Tumor cells could also 
migrate, guided by vasculature or nerve 
bundles which is termed ‘perineural invasion’. 
Glioma tumor cells migrate to form local or 
distant satellite lesions, or even mirror lesion in 
contralateral hemisphere, but metastasis 
outside the brain rarely exists [37]. Briefly, 4 
steps are involved in tumor invasion [35]: a). 
Invading cells detachment. Down regulation or 
inactivation of cadherin, functional in cell-to-
cell junction formation and stable structure 
maintenance, is thought to play a key role in 
this stage. b). Extracellular matrix (ECM) 
adherence. Integrin expression on glioma cells 
could induce adherence to ECM and upregulation of integrin on glioma cells. c). ECM 
degradation. Proteases, such as matrix-metalloproteinase (MMP), are produced by glioma 
cells and play a part in ECM degradation. This process is tightly related with the transcription 
factor NF-κB [35]. d). Motility and contractility. Similar to the migration pattern of stem cells 
in the mature brain or non-transformed neural progenitors during embryonic development 
cytoplasmic mediators, like myosin induce contractility capable of altering the shape of cells. 
1.1.2.4 Apoptosis resistance and survival signaling 
 
Apoptosis resistance and survival signaling in glioma could represent two sides of one coin. It 
refers to distinct processes in glioma-genesis. The apoptosis signaling network includes an 
extrinsic and intrinsic pathway [38]: as a death signal comes from outside the cell, like TNF-
α, FasL or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binding to their 
respective receptors TNFR1, CD95 or death receptor (DR)4/5, the intracellular death domain 
recruitment, continues with activation of the caspase cascade leading to DNA fragmentation 
and chromatin condensation. The intrinsic pathway is triggered by intracellular signals like 
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oxidative stress, DNA damage or insufficient growth factors. Proteins of the B cell 
lymphoma family are involved in the intrinsic pathway regulation [39]. Dysregulation of 
intrinsic or extrinsic pathway causes apoptosis resistance. For instance, BCL-2 and BCL-XL, 
which belong to anti-apoptotic BCL-2 family, could bind with pro apoptotic BCL-2 proteins 
and therefore inhibit the programmed death. Up-regulation of the anti-apoptotic BCL protein 
or down-regulation of pro-apoptotic protein would induce tumor growth. Then survival 
signaling pathways in glioma are cross-linked as a complex network. For instance, EGFR or 
platelet-derived growth factor receptor (PDGFR) binding induces receptor tyrosine kinase 
(RTK)/RAS/ Phosphtaidylionositol-3-kinase (PI3K) signaling dysregulation, the RB 
dysregulated pathway as well as the dysregulated TP53 pathway [40, 41]. 
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1.2 TUMOR BIOLOGY OF PANCREATIC CANCER 
1.2.1 Epidemiology, etiology and classification 
 
Pancreatic cancer arises from cells either from the exocrine (around 99%) or endocrine 
component within the pancreas. Pancreatic ductal adenocarcinoma (PDA) or pancreatic 
adenocarcinoma (PA), accounts for about 85% of pancreatic cancer. Pancreatic cancer is one 
of the most lethal tumors: it is reported that within 44,000 individuals with newly diagnosed 
pancreatic cancer in the US, around 80% of patients will succumb to the disease within one 
year [42]. Over the past 80 years, the death rates of most cancers exhibited a remarkable 
decrease, while the 5 year survival rate of PDA is still less than 5%, similar to that in the 
1980s and the 2000s. Even for patients (15-20%) who undergo curative resection, only 20% 
of them survive after 5 years, with no significant change in disease specific survival in the 
past 40 years [43]. Briefly, PDA is high aggressive with profound treatment resistance and 
poor prognosis. It takes many years for tumor progression, so with a median age at 71, PDA 
often occurs in the elderly population and 74% of patients are within the range of 55 to 84 
[44]. 
 
According to the American Joint Committee on Cancer (AJCC), 7th edition, pancreatic 
cancer is staged from 0 to IV based on the TNM system. Almost all of the pancreatic cancers 
are from epithelial cells, lymphoid neoplasms or primary mesenchymal tumors (e.g., 
sarcomas) are rare. 98% of pancreatic could be categorized according  the gross appearance: 
solid neoplasm which includes: PDA/PA, pancreatic endocrine neoplasm, pancreatoblastoma 
and acinar cell carcinoma; cystic neoplasm which includes intraductal papillary mucinous 
neoplasms (IPMN), mucinous cystic neoplasms (MCN) and solid-pseudopapillary  neoplasm 
[45]. 
 
Risk factors of pancreatic cancer could be grouped in three categories: genetic, environmental 
and medical risk factors. A positive family history, especially with a first degree case (parents, 
offspring or siblings) is a clear-cut risk factor; around 5-10% of pancreatic cancer is familial, 
yet genetic defects which had been discovered could only explain10-15% familial cases [46]. 
Concerning environmental factors, tobacco represents an independent risk factor of PDA, it 
takes as long as 20 years before the risk returns to baseline after smoking cessation [47]. 
Interestingly, cigars are also considered as a risk factor, while smokeless tobacco is not, the 
case is not clear for environmental smoke, such as air pollution or passive smoking. 
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Occupational hazards, like chlorinated hydrocarbons or PAHs, also increase the risk for PDA 
[48]. Whether alcohol consumption could be an independent risk factor of pancreatic cancer 
is still controversial. Yet frequent and excessive alcohol consumption is a cause of chronic 
pancreatitis, which serves as precursor for cancer. Chronic pancreatitis, diabetes and obesity 
are well accepted medical risk factors for pancreatic cancer. 
1.2.2 Cancer evolution 
 
Briefly, three stages are included in the evolution of pancreatic cancer [49]. Stage 1, risk 
factors of pancreatic cancer which have been listed before have impact on pancreas cells, a 
‘driver’ mutation occurs which induces cells to escape from apoptosis and senescence or to 
survive under immune-surveillance. As shown in Figure 3, it takes around 11.7±3.1 years to 
form the non-metastatic parental cell clone with driver mutations. Stage 2, clonal expansion 
(stepwise or punctuated progression model) which implies that co-mutations would result in 
genomic instability and heterogeneity of tumor lesions along with the appearance of ‘mixed’ 
metastatic cell sub-clones, 63 somatic mutations could be found per tumor lesion in PDA [50].  
It takes around 6.8±3.4 years for this stage. Stage 3, introduction to foreign 
microenvironments and index lesion formation. End stage of the disease with metastasis is 
approximately around 2.7±1.2 years. 
 
 
 
Figure 3. Genetic evolution of pancreatic cancer. Source: Distant metastasis occurs late during the genetic 
evolution of pancreatic cancer. Nature. 2010 Oct 28;467(7319):1114-7. 
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1.2.3 Genomic instability and proteomic signatures 
 
Signature mutations, included in the molecular profile of pancreatic cancer, are Kras, 
CDKN2A/P16, T53 and DPC4/SMAD4 [51]. Kras, located on chromosome 12, is a member 
of GTP binding proteins with intrinsic GTPase activity that transduces cellular proliferation, 
survival and differentiation signals [52]. Kras is detectable in almost all PDA cases and 
serves as a critical driver mutation. Cyclin dependent kinase inhibitor 2A (CDKN2A), located 
on chromosome 9, acts as a tumor suppressor gene, by inhibiting CDK4/6 dependent 
phosphorylation of the RB protein. CDKN2A inactivation could be found in 95% of PDA 
cases [53, 54]. CDKN2A is also involved in familial pancreatic cancer cases, known as 
familial atypical multiple-mole melanoma (FAMMM) syndrome. Patients are at risk of 
developing melanoma and exhibit a 12-22 fold increased risk to develop pancreatic cancer 
[55]. Located on chromosome 17, the tumor suppressor gene TP53 which is functional in cell 
cycle progression inhibition and DNA repair, is inactivated in 50-75% of PDA cases [53]. 
Deleted in pancreatic carcinoma, locus 4 (DPC4), located on chromosome 18, encodes a 
critical protein for TGF-β mediated growth inhibitory pathway, it is inactivated in 55% of 
PDA cases [55]. The most clinically relevant tumor marker for pancreatic cancer is CA19-9 
with a specificity of 90% and sensitivity of 70-90%, which is also meaningful in treatment 
assessment and prognosis [56]. Other proteomic signatures include CA50, cancer embryotic 
antigen (CEA), CA72-4, osteopontin, and the regenerating islet-derived protein 4 (REG4) 
[57]. 
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1.3 CANCER IMMUNOLOGY 
1.3.1 Tumor immunogenicity   
 
What represents the ideal target or a desired profile of a successful immunotherapy against 
cancer? Similar to infectious diseases, immunogenic responses should be long-lived which 
ensures that tumor cells could be recognized and then eliminated mainly by T cell responses. 
Tumor immunogenicity refers to the susceptibility of being targeted by the host immune 
response, and it may be associated with the antigenicity of tumor cell itself or from 
immunomodulatory products which are produced by the host or the tumor cells in the tumor 
microenvironment. 
 
Tumor antigens are processed and presented as epitopes on major histocompatibility complex 
(MHC) class I or II molecules which could be recognized by T cells in the form of the MHC-
peptide-TCR complex. Expression of MHC-I molecules is detectable on almost all nucleated 
cells, including tumor cells, which can be targeted by CD8+ T cells. MHC-II molecules are 
expressed on professional antigen-presenting cells (APCs) such as dendritic cells, 
macrophages, or B cells, which could be recognized by CD4+ T cells. MHC class II 
molecules could also be induced by IFN-ߛ	on professional APCs. Several possibilities are 
available for the identification of tumor antigens. Expression cloning refers transfecting the 
tumor cDNA library into cells, followed by the ability of transfected cells in activating T-cell 
clones, gene-encoded peptides would be further tested for MHC affinity and target cell 
recognition [58]. Serological Analysis of cDNA expression library (SEREX) is a similar 
approach with the difference that the responsible gene encoding tumor antigen was defined 
via serum identification [59]. Another promising, but technical demanding, represents mass 
spectrometry. After immune-purification of MHC-I molecules together with the loaded 
peptides, peptides are eluted and then sequenced [60]. A new approach, reported by the group 
of Steven Rosenberg in 2014, a patient specific mutation database established by sequencing 
of the entire exons of the tumor; the identified peptides would undergo MHC molecule 
binding prediction and a tandem mini-gene would be employed in epitope exploration and to 
test whether the target is naturally processed and presented to T cells [61]. 
 
Based on the specificity and origin, TAAs could be divided into two groups and five 
subgroups (Figure 4).  
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Figure 4. Tumor antigens. Source. Human Tumor Antigens and Cancer Immunotherapy. BioMed research 
international, 2015: p. 948501. 
 
Antigens with high tumor specificity could be derived from viral proteins, mutations or 
germline line encoded proteins. A different group represents antigens with low tumor 
specificity, which includes differentiations or ‘overexpressed’ antigens. Around 15-20% of 
all human cancers are virus infection related [62]. A virus that could cause cancer, such as 
Kaposi's sarcoma-associated herpesvirus (KSHV), Hepatitis C virus (HCV), Epstein–Barr 
virus (EBV), Hepatitis B virus (HBV), Human papillomavirus (HPV), is called ‘onco-virus’. 
An HPV vaccine which could induce HPV-16 specific immune response is now well 
accepted as a protection of HPV infection [63]. Therapeutic HPV vaccinations have also been 
successfully performed using ‘long peptides’ [63] and HPV-specific TCRs are used at the 
NIH (NCT02280811). Tumor mutations happen frequently, but not all mutations are involved 
in tumorgenesis, many of them emerge randomly such as mutations associated with 
cancerogens or radiation called ‘passenger mutations’, KRAS, EGFRvIII, TP53, IDH or 
CDKN2A mutations are called driver mutations and play a role in malignant transformation. 
Products from both conditions would be classified as TAAs. Cancer germline genes encoded 
proteins are another important source of TAAs. Located on X chromosome, the cancer 
germline genes could be expressed normally on trophoblastic or germline cells, or on tumor 
cells, known as cancer-testis antigens (CTAs). Gene products such as NY-ESO-1, MAGE, 
BAGE, GAGE belong to this group [64]. Differentiation antigens, such as CEA, gp100 or 
Melan-A/ MART-1 refer to antigens which could be expressed either in a given type of tumor 
or normal corresponding tissue. Similarly, overexpressed antigens such as WT1, HER2 or 
mesothelin could exist within healthy tissue, but increased expressions are detectable within 
certain tumor types.  
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1.3.2 Immunosurveillance 
 
Immuno-surveillance refers to the function of the immune system that keeps foreign 
pathogens and malignant transformation ‘in check’. Paul Ehrlich is perhaps the first person 
who introduced the concept of cancer immunosurveillance in 1909. He predicted that cancer 
would occur frequently if host defenses would not prevent the outgrowth of continuously 
arising cancer cells. The concept of immunosurveillance was first raised by Burnet and 
Thomas in 1957. Discovery of immune surveillance of tumors was proved in a mouse model 
by tumor transplantation experiments using syngeneic mouse strains. Increased incidence of 
EBV+ B cell lymphomas in transplant patients treated with immunosuppressive drugs and 
increased incidence of Kaposi’s sarcoma and EBV+ B cell lymphomas in AIDS patients also 
serve as evidence for immunosurveillance in humans. One may argue that cancers, which 
occur spontaneously within the immune-competent population, are not under surveillance of 
the host immune system. Furthermore, many cancers may develop since the host immune 
system fails to discover them in situ, this will refers to the concept of ‘tumor immune escape’. 
1.3.3 Tumor microenvironment 
 
If a tumor is considered as a ‘malformed organ’ instead of a random collection of malignant 
transformed cells, one would predict that tumor cells may even exceed healthy tissue in 
complexity and efficiency. Based on this observation, the concept of the ‘tumor 
microenvironment’ which reflects the crosstalk between malignant and non-transformed 
cells, as well as the dynamic network of cytokine is proposed. It was discussed that even the 
non-transformed cells, supporting malignant cells, should be also targeted in immunotherapy 
to achieve tumor clearance, as shown in preclinical animal models [65]. Undisputedly, cancer 
cells orchestrate and establish the complex environment via recruiting and instructing non-
transformed cells localized or circulated to serve as supporting members. By physical contact 
or via the cytokine network, tumor cells specialize in ‘convincing’ and ‘taming’ normal cells 
into their ‘accomplice’. Apart from tumor cells within tumor microenvironment, constituents 
of cancer stromal includes the tumor related vasculature and lymphatics, tumor infiltrating 
immune cells, cancer-associated fibroblasts, as well as pericytes and sometimes adipocytes  
[66] (Figure 5).  
 
Cytokines such as VEGF, EGF, platelet-derived growth factor (PDGF)， fibroblast growth 
factor (FGF) and chemokines produced by tumor cells, or other stromal component could 
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keep the ‘angiogenic switch’ on, which means that endothelial cells could establish neo-
vasculature with supporting pericytes [67], abnormal in both structure and function. For 
instance, heterogeneous neo-vessels could be found with uneven lumen, incomplete vessel 
wall and chaotic branching structures inducing leakage, uneven distribution of oxygen and 
nutrition [68]. A hyper-proliferative state of the tumor lesion could be impaired via inhibition 
of angiogenesis, which has already been used in clinical trials [67]. Immune cells infiltrating 
locally are either inhibited or silenced in function, or they act as tumor supporters within the 
tumor microenvironment. Beside tumor cells, immune cells are the main source of immune-
suppressive cytokine like IL-10 or TGF-β. Other tumor promoting cytokines, induce 
mitogenic growth mediators which could stimulate proliferation of neoplastic cells and 
production of proteolytic enzymes, which could induce the modification of extracellular 
matrix (ECM) [69]. Within the tumor lesion, CD8+CD45RA- T cells and TH1 polarized 
inflammation, characterized by IL-2 and IFN-γ production, are associated with a better 
prognosis, while Treg (CD25highFOXP3+) cells, TH17 cells or TH2 polarized inflammation 
are linked with tumor progression [70]. γσ T cells are potent in anti-cancer activity, even 
against cancer stem cells. However, the linkage of the presence of γσ T-cells and prognosis in 
cancer patients is less clear [71]. Nature killer (NK) cells or NKT cells, which are innate 
cytotoxic lymphocytes, predict a better prognosis in certain cancer histology, but they appear 
not to exert killing in most cases, due to the suppressive tumor microenvironment [66]. 
Tumor infiltrating B-cells which could be found in draining lymph nodes and tumor invasive 
margins are reported with good prognosis only in several certain cancers and could play an 
role in tumor-promoting [72]. Clinical evidence showed that abundance of macrophages 
within tumor lesion is associated with poor prognosis. An unbalanced M1 macrophages 
(defined by production of IL-1, IL-12, IL-23 and chemokines) and M2 macrophages (defined 
by production of IL-10 and TGF-β) within the tumor is usually the case, where the M2 
dominant environment could induce angiogenesis and immune-suppression [73]. Myeloid-
derived suppressor cells (MDSCs) are defined as inhibitory immune cells, which could 
induce M2 polarization, Treg development and CD8+T cell inhibition [74]. Dendritic cells 
(DCs), professional APCs, are either defective or exist with impaired functions in the tumor 
micro-environment. They may not be able to immune-responses, or even worse, DCs have 
been reported to function as T cell suppressors by loading with ‘suppressive epitope’ 
(presented to T cells) or by activating Tregs. Cancer-associated fibroblast cells (CAFs) 
encompass distinctive cell types, such as activated connective tissue fibroblasts, proximal to 
tumor lesions, or myofibroblasts derived from mesenchymal stem cells (MSCs), either local 
or bone marrow orginated [75]. CAFs are significant in tumor niche formation and could 
 25 
 
produce tumor-promoting growth factors like insulin-like growth factor1 (IGF1), hepatocyte 
growth factor (HGF) and FGF. The epithelial-mesenchymal transition (EMT), which is 
essential for tumor microenvironment building and metastasis induced by TGF-β, is 
positively affected by enzymes, produced by CAFs [76]. 
. 
 
 
Figure 5. Tumor microenvironment with cytokine network. Source: Hallmarks of cancer: the next generation. 
Cell, 2011. 144(5): p. 646-74. 
1.3.4 Tumor immune escape in glioma and pancreatic cancer 
 
Different types of mechanisms have been demonstrated in immune escape of cancer cells. 
Tumor cell can simply ‘outpace’ the immune response by fast proliferation, or the tumor cells 
hide in immune-privileged sites. Loss of T cell recognition could be caused by: (1). Mutation 
or down regulation of tumor antigens [77]. (2). Down modulation and reduced expression of 
MHC-I and/or MHC-II molecules on tumor cells [77], (3). Loss of transporter associated with 
antigen processing (TAPs), low molecular mass poly-peptide (LMP) or other molecules 
involved with antigen processing [78]. (4). The tumor may generate intrinsic resistance to 
apoptosis by over-expression of bcl-2 [79], bcl-xL [80] or other inhibitors of apoptosis 
proteins (IAPs). (5). Frequency of Tregs may also increase within the tumor 
microenvironment and cause the tumor to facilitate generation of regulatory T cells [81]. 
Amino acid depletion derived metabolic immunosuppression could be another mechanism, 
ie. Arginine depletion would lead to down modulation of the TCR ζ chain or NF-κB, leading 
to defect activity of T cells and subsequent suppressed immune effective functions [82]. 
Tumor or tumor recruited Tregs may also produce inhibitory cytokines like IL-10 or TGF-β 
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[83]. Several malignancies, including neuroblastomas could up-regulate expression of 
macrophage migration inhibitory factor (MIF), inducing T cell activation blockage and T cell 
apoptosis [84]. Tumor cells could also express Fas ligand (FasL) which would induce 
apoptosis of T-cells. Up-regulation of ligands, like PD-L1 on tumor cells, receptor-binding 
cancer antigen expressed on SiSo cells (RCAS1) or CD200, which will bind to negative 
regulatory receptors on T cells may also lead to T cell suppression [85].  
 
The brain was previously thought as ‘immune privileged ’site, due to the existence of the 
blood-brain barrier (BBB). It is now well accepted that the brain has a well established 
immune network with a frequent crosstalk with the bodies’ immune system. Microglia, act as 
the localized ‘troops of immune system’ within the brain, it keeps potential pathogens in 
check and removes the neurotoxic debris via phagocytosis. Structurally high vascularity areas, 
like the choroid plexus, the leptomeninges or circumventricular organs, which lack the BBB, 
could facilitate the exchange of proteins and cells [86]. The adaptive immunity was before 
considered to be limited within the brain due to the absence of lymphatic channels. The 
existence of functional lymphatic vessels, lining in the dural sinuses and connecting to deep 
cervical lymph nodes was reported as new channels for immune cell communication [87]. 
Even further, the disrupted BBB will allow immune cell infiltration in the case of glioma 
development. 
 
Mechanisms employed in glioma immuno-escape are numerous. Despite the physical barrier 
of the BBB, microglia that may account for up to 30% of the glioma tumor mass, along with 
the tumor microenvironment, may produce cytokines including IL-6, IL-10, TGF-β, 
Prostaglandin E2 (PGE2), IL-1, CSF-1, MIC-1,EGF, Matrix Metalloproteinases (MMP), 
VEGF that suppress immune effector cells, promote tumorigenesis, induce M2 polarization 
and promote tumor invasion and migration [88-94]. CD70, gangliosides,PD-L1, CTLA4, 
CCL22, CCL2 and FasL expressed by GBM cells would induce apoptosis of cytotoxic T cells 
and attracts Tregs to the tumor site [95-97]. Similarly, pancreatic cancer also induces immune 
escape in the form of a suppressive microenvironment and suppressive cytokine networks 
[98-100]. 
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1.4 IMMUNOTHERAPY FOR GLIOMA AND PANCREATIC CANCER 
1.4.1 Non-targeted treatment 
 
Current conventional standard treatment modalities for glioma include surgery, chemotherapy 
and radiation, while radiotherapy for pancreatic cancer is rarely applied. A first line 
chemotherapeutic agent for GBM is temozolomide which could increase the median and 2 
year survival of patients with GBM by 2.5 months and 16.1% respectively [101]. 
Temozolomide is an oral drug that induces methylation of DNA at guanine residues of O6 or 
N7 position, such a methylation would induce DNA damage and cell death. Notably, some 
tumors with un-methylated promotor region of MGMT would be able to generate activated 
MGMT, which could repair the methylation damage induced by temozolomide; this is linked 
with poor prognosis [102]. Another combination drug for glioma treatment is lomustine 
which is an alkylating nitrosourea compound, that can cross the BBB easily [103]. 
Comparably, gemcitabine is the first consideration in PDA chemotherapy. As a difluorinated 
analog, gemcitabine blocks DNA replication in tumor cells which is related with treatment 
benefits in patients with PDA [104]. Even compared with 5-flluorouracil (5-Fu), which is 
another extensively used first-line anti-PDA drugs, gemcitabine showed its clinical survival 
in improving overall survival (OS) [105]. Gemcitabine based combination such as 
capecitabine, cisplatin or oxaliplatin  in distinct clinical trials are explored and evaluated 
[106]. 
1.4.2 Monoclonal antibodies (mAbs) 
 
Monoclonal antibodies (mAbs) may recognize TAAs in a MHC unrestricted manner and 
induce tumor cell death in various ways. Since glioma is defined as tumor with high 
vascularity, mAbs which target angiogenesis, such as VEGF as a monotherapy or in 
combination with other drugs, could achieve promising outcomes. Bevacizumab/Avastin 
(anti-VEGF mAb) binds to VEGF and neutralizes its biological activity so the downstream 
angiogenesis signaling is blocked [107]. EGFRvIII is detected in around 20-30% of GBM 
cases and involved in tumorigenesis and induction of chemotherapy resistance [108]. 
Cetuximab, a recombinant chimeric mAb with EGFRvIII specificity, is engaged in the 
EGFRvIII signal pathway with encouraging clinical results [109]. AMG595, an anti-
EGFRvIII mAb and cytotoxic agent conjugated drug, is currently tested in clinical trials 
(NCT01475006). Similarly, Cetuximab is also involved in clinical trials for advanced PDA, 
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due to the key role of EGFR signal pathway in PDA pathogenesis. EGFR is overexpressed in 
90% of pancreatic cancer cases and could serve as an immuno-target. Erlotinib, an anti-
EGFR mAb, together with gemcitabine showed a reliable clinical improvement in one phase 
III trial [110]. Other mAbs like ganitumab or dalotuzumab which are specific to insulin-like 
growth factor (IGFR) have also been employed in pancreatic cancer therapy. Certain groups 
of mAbs, like checkpoint inhibitors, will be discussed below. 
 
1.4.3 Vaccine based therapy 
 
The aim of vaccine therapy is to induce and harness host adaptive immune response to tumor 
antigens actively via cell-based or non-cell based approaches. Anti-cancer directed immune 
response could be established de novo or by boosting pre-existent tumor specific memory 
cells. Potential antigens employed in cancer vaccine therapy may include: TAAs peptides or 
loaded to APCs, tumor cells with or without genetic modification, e.g. plasma DNA or 
vectors which encode TAAs. Vaccines targeted only a single tumor antigen appears to be 
associated with immune escape inevitably, so at least two or more antigens may be necessary. 
In order to broaden anti-tumor activity and to reduce tumor escape, immunoadjuvants are 
usually included, such as poly-ICLC which are stable dsRNAs and potent in IFN-γ induction. 
IMA-950, consists of 11 glioma tumor specific antigens, mainly with HLA-A2 and HLA-
DRB1 restriction,IMA950 is a peptide-based vaccine, in combination with other drugs, or 
adjuvants that is broadly employed in different clinical trials in GBM vaccination [111]. SL-
701, a combination of tumor antigens (IL13Rα2, HER2, gp100, MAGE-1 AIM-2) which are 
expressed in 75% of HLA-A1/2 glioma samples, has been tested with safety and tolerability 
outcome and showed clinical benefit [112]. Kras as a driver mutation in pancreatic cancer, 
was first tested in a peptide vaccine and 40% of patients showed prolonged survival in a 
phase I/II study [113]. Other tumor antigens like telomerase, gastrin or heat shock protein 
(HSP) also served as targets in a peptide-based vaccine against pancreatic cancer. HSP is 
generated under stress environment, such as inflammation or hypoxia. Similar to peptide-
based vaccines, proteins such as HSP or CMV pp65 are involved in certain trials for glioma 
vaccination [114, 115]. Tumor cells could be candidates for vaccines, either directly as whole 
tumor cells or loaded onto dendritic cells as tumor lysates. In the case of glioma, autologous 
tumor cells with Newcastle disease virus (NDV) have been reported as vaccines [116]. This 
virus could selectively replicate in tumor cells to start an immune reaction in situ. Applied for 
pancreatic cancer, the GVAX pancreas vaccine is a whole tumor cell vaccine established with 
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a gene modified allogeneic pancreatic cell line with GM-CSF producing capacity [117]. 
Autologous dendritic cells (DCs) are the most commonly used APCs as a tumor vaccine due 
to their distinguished ability in activing the innate and the adaptive immune system. Glioma 
specific antigens such as EGFRvIII, CD133, HSP, SL701, IMA950 or glioma tumor lysates 
could be loaded onto autologous DCs or other APCs directly or through an intrinsic process 
(gene modified) and then recognized by the host adaptive immunity.  
1.4.4 Checkpoints Inhibitors 
 
Immune checkpoint mediators are to prevent excessive activation of immune system and to 
restrict immune response within to minimize the risk of autoimmune reactions. Pathological 
processes, like tumors, take advantage of this protective mechanisms and induce an 
immunosuppressive environment via those inhibitor checkpoint mediators, like cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4) or the programmed cell death protein 1 (PD-1) to 
drive tumor specific effector cells into exhaustion or ‘anergy’. In this case, therapeutic 
blockage of these inhibitory mediators would be linked to anti-tumor benefits which had been 
demonstrated in several cancers [118, 119]. CTLA-4 is expressed as a ‘late co-stimulator’ 
inducer to attenuate T cell activation and to induce memory T cell generation. Monoclonal 
antibodies against CTLA-4, like Ipilimumab, could inactivate signals downstream of CTLA-
4 and reverse the destiny of tumor specific activated T cells. PD-1 expressed by antigen 
experienced T cells, could induce anti-tumor responses and also possibly autoimmune 
diseases. The PD-1 ligand could be expressed on tumor cells or tumor helper cells which 
would then cause T cell death by binding with PD-1 molecules. mAbs which could block PD-
1 like Nivolumab, Pembrolizumab or PD-L1/2 like duravalumab, may rescue TAA-specific 
T-cells from apoptosis.  
  
1.4.5 Adoptive cellular immunotherapy (ACT) 
 
Adoptive cellular immunotherapy (ACT) has been first reported in 1990 by Kolb et al. after 
the treatment of chronic myeloid leukemia patients using donor leukocyte infusions (DLI) 
[120]. In 2002, Steven A. Rosenberg (NIH, DC, USA), reported that the passive transfer of 
highly specific tumor infiltrating T cells (TILs) directed against tumor differentiation antigens 
(i.e. Melan-A/MART-1, gp100) leads to durable regression in patients with metastatic 
melanoma. TILs showed a restricted TCR repertoire – which was also detectable after passive 
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TIL transfer in lympho-depleted hosts. The transfer and proliferation of T cells resulted in the 
regression of the patients’ metastatic melanoma [121]. Genetically engineered lymphocytes 
induced cancer regression in patients has also been reported by Steven Rosenberg et al. in 
2001 [122]. Here, MHC-class I and peptide-specific monoclonal TCRs were genetically 
expressed in recipient target cells which acquired the specificity of the transferred TCR. An 
‘immune escape’ mechanism is the lack of a sufficient TCR repertoire capable of effectively 
recognizing tumor cells, a concept that has been called ‘tumor – editing’: long-term infection 
or tumor cells shape the TCR repertoire and lead to preferential expansion of T-cells that 
could potentially favor the life-cycle of the pathogen or proliferation of tumor cells (e.g. by 
production of growth factors). Alternatively, antigen-specific T-cells may exist, yet they are 
non-functional, they exhibit ‘anergy’ [123-125]. Therefore, functional deficiencies of 
antigen-specific cells, as well as a quantitative lack of antigen-specific T-cells in patients with 
infections (or tumors) call for a passive transfer of a T-cell product with a specific TCR that 
targets the nominal MHC class I/peptide complex on infected or transformed target cells (e.g. 
EBV, CMV, Adenovirus or tumor associated antigens, i.e. NY-ESO-1, EGFRvIII which are 
frequently expressed in glioma). 
 
T cells are specialized in target specificity and functional tumor killing. In certain conditions, 
it may even negotiable to sacrifice the functional part of an organ (‘disposable tissue’) and 
pay attention only to the cancer specificity: one could regenerate genetic modified effector 
cells via TCR transfection. Similarly, T-cells can be endowed with chimeric antigen receptors 
(CARs) One potential advantage of ACT when comparing with vaccine-based strategies: the 
former is less limited by the clinical states of the patients, particularly when patients are 
immune compromised. T cells from several sources could be employed in ACT: TILs, 
PBMCs or engineered T cells. TILs are highly tumor specific, but TILs may be assimilated 
and inhibited by the tumor microenvironment, while the subdued state of TILs may be 
overcome during the ex vivo expansion with cytokines. Expanded TILs could be infused 
back for ACT as shown with clinical benefits in patient with melanomas [121]. TILs 
expanded with IL-2 were infused to 6 patients with recurrent malignant glioma in 1999. One 
patient showed complete response with 45month follow-up, and two achieved to partial 
response [126]. Re-infusing of enriched TILs from pancreatic cancer tumor tissue is tested in 
one ongoing phase II study (NCT01174121). Even though PBMCs are easier manipulated to 
meet the clinical requirement, the challenge is to enrich tumor specific T-cells. TCR 
transfection is one of the choices. For achieving this goal, Ag-specific T-cell clones are 
needed as the primary source for the specific TCR genes which can be transferred into target 
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cells, usually using a retroviral or lentiviral transfer system.  Some tumor Ag-specific T-cells 
clones have already been established and tested in phase I clinical trials, as MAGEA3 HLA-
A*0101-EVDPIGHLY, NY-ESO HLA-A*0201-SLLMWITQC, the MAGE-1 HLA- 
Cw*1601- SAYGEPRKL restricted T cell clone or the Kras G12D HLA-C*08:02 specific T 
cell clone[127]; the TCR gene cDNA sequences were isolated from the T-cells clones, after 
initial functional testing and validation, followed by creation of a retroviral vector which 
could encode a T cell receptor (TCR) specific for the nominal target antigen. Genetically 
fusing extracellular binding domains such as tumor antigen specific IgG with an intrinsic 
signaling domain could generate effector CAR T cells, which recognize antigens in a MHC 
independent way. CD133, EGFRvIII, IL13Rα2 or HER2 specific CAR T cells are 
undergoing clinical exploration in a series of clinical trials (NCT01109095, NCT00730613, 
NCT01082926, NCT01454596). In pancreatic cancer, genetic modified TCR or CAR T cells 
are targeting mesothelin or survivin in different trials (NCT01583686, NCT01967823, 
NCT02239861). 
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2 AIMS OF THE THESIS 
 
The general aim of this thesis is to expand functional tumor specific T cells from peripheral 
blood or tumor section/biopsy of patients with glioma or pancreatic cancer which could be 
potentially be used for cellular immunotherapy. This would enable that TAAs-specific TCRs 
could be isolated and sequenced for further potential clinical use. We also attempted to 
understand relations between peripheral blood immune reactions against tumor antigens as 
predictors and patients overall survival (OS). 
 
Specific aims 
 
 To expand Tumor infiltrating lymphocytes (TILs) from fresh tumor tissues using IL-2, 
IL-15, IL-21 to large scale. Tumor tissues are received from surgical resections or 
from biopsy of patients with glioma or pancreatic cancer. The TIL specificity, 
clonality and function will be defined. (Paper I and II) 
 
 To define expression of NY-ESO-1 and survivin in glioma tumor lesions and relevant 
T cell response in peripheral blood immunoreaction together with further attemptions 
to expand functional NY-ESO-1 or survivin specific T cells from autologous PBMCs 
or TILs of patients with glioma. (Paper III) 
 
 To define expression of mesothelin in glioma tumor lesions and relevant ex vivo 
peripheral blood immuno-reactions. (Paper IV) 
 
 To define ex vivo peripheral blood immunoreaction against a list of viral and tumor 
antigens in patients, with glioma, to explore linkage of antigen immune responses 
with patients overall survival (OS). (Paper V) 
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3 RESULTS AND DISCUSSION 
3.1 Tumor-infiltrating lymphocytes (TILs) from patients with glioma or 
pancreatic cancer (Paper I and II) 
 
TILs could reliably be expanded from surgical resections or biopsy specimens from 17 
patients with pancreas cancer and 16 patients with glioma up to 1010 cells using the IL-2/IL-
15/IL-21 cytokine cocktail with a dominant CD3+ phenotype. The benefit of combining IL-2, 
IL-15 and IL-21 in TIL expansion could be due to several factors, e.g. IL-21 has been shown 
to promote expansion of TILs with strong cytotoxic potential [128], it rescues CD8+ T-cells 
from suboptimal antigenic stimulation and it has been shown to stimulate high affinity T-cells 
without the need for CD8 help [129]; IL-15 and IL-21 may therefore aid to expand ‘better’ T-
cells with increased frequencies of antigen-specific responses residing in long-term memory 
T-cell subsets [130]. The preferential expansion of central memory and effector T-cell 
subsets, defined by CD45RA-CCR7+ and CD45RA-CCR7- expression in both glioma and 
pancreatic cancer cases, appears to be associated with the nature of T cell source, since IL-21 
may have minimal effects on ‘resting’ cells but could selectively expand T cell in the 
activation state. TILs with certain characteristics which refer to distinct effector functions and 
homing patterns are necessary for clinical responses [131]: Central memory T-cells 
(CD45RA-CCR7+) have been linked with stronger proliferative potential and are the best 
candidates to provide potential long-term anti-tumor protection [132, 133]. Central memory T 
cells are reported to relate with better prognosis and long-term (up to 3 years) remissions in 
some cases [134].  
 
TILs were further characterized for expression of “activation-exhaustion” cell surface 
markers exhibiting a low median frequency of 4-1BB, CTLA-4, LAG-3 and TIM3 positive 
cells in CD3+ TILs, whereas PD-1+ T-cells could be an indication of tumor antigen 
experienced cells that could potentially be further expanded ex vivo. TILs with Treg 
phenotype (CD3+CD4+CD25highCD127-Foxp 3+) are not detectable in both tumor 
histologies. 
 
The function of T cells refers to cytotoxicity and/or cytokines like IFN-γ, TNF-α and IL-2 
against autologous tumor or TAAs. Cytotoxicity can be tested via CD107a Assay or the Cr51 
release assay, while cytokines could be measured by enzyme-linked immunosorbent assay 
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(ELISA) or intracellular cytokine staining (ICS). TILs expanded either from glioma or 
pancreatic cancer samples have been shown to react to autologous tumor cells defined by 
cytotoxicity and cytokine production. TILs have also be shown to react to TAAs i.e. 
mesothelin, NY-ESO-1 and survivin (Figure 6). Both tumor specific cytotoxicity and 
cytokine productions could be blocked by anti-MHC-I/II Abs which means the tumor specific 
immune response are based on MHC class I/II- TCR interaction. 
 
 
Figure 6. Immunoreaction of TILs from glioma against autologous tumor cells. A. Cytokine production of TILs 
in different subpopulations. B. Autologous tumor cell specific cytotoxicity of TILs defined by Cr51 release 
assay. 
 
Clonality of TILs from either glioma or pancreatic cancer samples were defined via flow 
cytometry-based Vβ analysis and polymerase chain reaction (PCR)-based clonality analysis. 
Preferential expansion of certain TCR Vβ clones were detectable in both tumor origins 
(glioma and pancreatic cancer), Some TCR Vβ families were shown to monoclonal or 
oligclonal proved by PCR and DNA sequence. One dominant TCR Vβ monoclone, after 
expansion, was tested for reactivity with autologous tumor cells. (Table 2)  
 
TIL id Vβ Vβ (-D-) Jβ Jβ Flow antibody
GBM A-CD4 TRBV20-1 CSA ATGDRP YEQYF TRBJ2-7 Vβ2 
GBM A-CD8 TRBV10-3 CAI RTGSD NEQSF TRBJ2-1 Vβ12 
GBM A-CD8 TRV11 CAS RYTGS IEQFF TRBJ2-1 Vβ21.3 
GBM F-CD4 TRBV27 CAS SAGTSGVT YEQYF TRBJ2-7 Vβ14 
GBM G-CD4 TRBV6-1/5/6 CAS STR FEQYF TRBJ2-7 Vβ13.1 
GBM H-CD8 TRBV12-3/4 CAS SSRRDHTY NGQFF TRBJ2-1 Vβ8 
GBM H-CD8 TRV27 CAS SLQGAN YGYTF TRBJ1-2 Vβ14 
GBM I-CD4 TRBV20-1 CSA RVIPSGGVVQGT DTQYF TRBJ2-3 Vβ2 
GBM I-CD8 TRBV5-1 CAS SWDKS YEQYF TRBJ2-7 Vβ5.1 
GBM J-CD4 TRBV11 CAS SRLALFS YEQYF TRBJ2-7 Vβ21.3 
 
Table 2. TILs Vβ sequence after preferential expansion. 
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Figure 4.  Angiogenetic switch.  Source: The 
scientific contributions of M. Judah Folkman to 
cancer research. Nature Reviews Cancer 8, 647-654. 
Figure 7.  NY-ESO-1 immunohistochemistry   
3.2 NY-ESO-1-specific T-cell responses in PBMCs from patients with 
glioma (PAPER III) 
 
Immunohistochemistry was used to test for survivin (n=40 samples) and NY-ESO-1 (n=38 
samples ) expression in tumor specimens. 50% of samples were defined as ‘high’ (≥20%) 
expressing survivin and 39.4% of samples were NY-ESO-1 expression-positive (≥5%) 
(Figure 7). NY-ESO-1 expression in 
glioma was found to be low in a single 
study [135] as compared to the current 
report. A possible explanation for this 
difference may be the selection of patients. 
The patients in our cohort were patients 
with a primary tumor who did not receive 
radiation or any prior chemotherapy [136]. 
NY-ESO-1 expression was also found to 
be patchy; limited access to tumor 
material may therefore result in false 
negative results concerning protein expression. NY-ESO-1 and survivin expression was 
consolidated by the presence of humoral anti-NY-ESO-1 and anti-survivin directed IgG 
responses [137, 138] in the patient cohort. NY-ESO-1 expression in glioma may open new 
therapeutic options, given the recent success of anti-NY-ESO-1 directed transgenic TCRs (for 
HLA-A2+) individuals [139, 140], the use of anti-NY-ESO-1 directed antibody therapies 
[141], or the use of anti-NY-ESO-1 directed vaccination strategies [142].  
 
NY-ESO-1 and survivin were tested to drive cellular proliferation and IFN-γ production in 
blood from patients with glioma. We identified an association of tumor associated antigens 
(TAAs)-reactive T-cells (defined by IFN-γ production) in correlation with the 
histopathological grading of the tumor and T-cells cultured with IL-2/IL-15 and IL-21. 
Stronger IFN-γ production was identified in PBMCs from patients with histopathological 
grade III tumors as compared to patients with a grade IV tumor in response to NY-ESO-1 (p 
= 0.0135), as well to the survivin peptide mix (p = 0.0062, supplementary). The proliferation 
ratio was increased using IL-2/IL-15/IL-21 as compared to IL-2/IL-7 for NY-ESO-1 (p = 
0.0014) driven T-cell expansion. The proliferative capacity of PBMCs in response to TAAs 
suggested that NY-ESO-1 or survivin directed T-cells can be expanded and may be used for 
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Figure 8.  NY-ESO-1 and survivin induced cell 
proliferation.   
the cellular therapy of patients with glioma. Furthermore, NY-ESO-1 tetramer+ sorted or 
INF-γ captured NY-ESO-1 directed T-cells were shown to recognize naturally processed and 
presented NY-ESO-1 epitopes on glioma tumor cell lines suggesting that peptide-driven 
expansion of T-cells leads to biologically and clinically relevant T-cell populations directed  
against tumor cells (Figure 8). 
 
In order to evaluate the cytokine production at a single cell level, we expanded PBMCs (after 
ficoll separation) from 5 patients with the NY-ESO-1 or the survivin peptide mix in the 
presence of IL-2/IL-15/IL-21, tested for T-cell 
maturation (based on CD45RA/CCR7 and T-cell 
activation markers, including 4-1BB. We found a 
trend of increase in central memory and effector 
memory T cells and also 4-1BB expression after 
expansion. Anti-NY-ESO-1 reactivity was 
confirmed by MHC-class I (HLA-A2+) –peptide-
tetramer guided staining showing up to 9.25% 
HLA-A2+ (NY-ESO-1) reactive T-cells. 
 
The numbers of cellular therapies directed against 
tumor – associated antigens for patients with 
gliomas are limited up to now; a review of cell-based therapies suggests that infusion of 
immune cells may lead to improved survival along with limited therapy associated toxicity 
[126, 143-146]. For instance, PBMCs were harvested for cellular therapy and CTL were 
generated directed against autologous (glioma) tumor cells (using a mix of PBMCs, 
autologous tumor cells and recombinant IL-2), followed by in situ administration (108 up to 
109 T-cells i.t.). 3/5 patients did not exhibit any benefit; 1/5 patient showed a transient 
regression and 1/5 a complete regression that lasted 104 weeks [147]. The data in our report 
show that NY-ESO-1 and survivin is can now be added as  a tumor-specific target for the 
biological treatment of patients with glioma particularly since data from several NY-ESO-1 
[7] or anti – survivin [148] directed trials did not suggest major toxicity. 
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3.3 Mesothelin as a novel biomarker and immunotherapeutic target in 
human glioblastoma multiforme (Paper IV) 
 
Mesothelin is a 40 kDa tumor differentiation antigen present on normal mesothelial cells, but 
overexpressed in mesothelioma, meningioma, ovarian cancer, lung and pancreatic 
adenocarcinomas [10, 149]. Mesothelin expression is closely related with prognosis [150-
154]. Full-length, unprocessed mesothelin precursor comprises two components, namely the 
31 kDa megakaryocyte-promoting factor (MPF) [155] and the membrane-anchored, 40 kDa 
mesothelin-glycoinositolphoslipid (GPI) component. MPF is cleaved by furin and shed into 
systemic circulation, and has been evaluated as a more accurate biomarker as compared to the 
full-length mesothelin for the immunodiagnosis of mesothelioma. Cell membrane-bound (or 
mature) mesothelin selectively binds to mucin 16 (MUC16) [156], which is expressed in the 
peritoneum, pleural cavities, mucosal surfaces and the brain, and has been shown as a 
promising target in immunotherapy [157-160]. We confirmed the overexpression of 
mesothelin with ratio of 36.4% (4/11) in GBM tissue by immune-histological staining of 
mesothelin protein in paraffin-embedded tissue sections visualized via fluorescence 
microscopy (Figure 9) 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. immune-histological staining of mesothelin 
 
Mesothelin (mesothelin peptide pool (297-630aa)) was tested to drive IFN-γ production in 
blood from patients with brain cancer in different histology and grade. Within three 
conditions of co-incubation (no cytokine,IL-2/15/21 or IL-2/7), we found that conditioning of 
whole blood from GBM patients with IL-2, IL-15 and IL-21 significantly improved the IFN-γ 
response to the mesothelin peptide pool, as well as the MPF and mesothelin precursor 
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Figure 10. Full length mesothelin mapping 
subcomponent. Conditioning of whole blood with IL-2 and IL-7 resulted in a stronger IFN-γ 
response to all three antigens (i.e. mesothelin precursor, MPF and mesothelin) although to a 
lesser degree than the combination of IL-2, IL-15 and IL-21. The finding was similar for 
patients with astrocytoma, oligoastrocytoma/ oligodendroglioma (OA/OD) and metastatic 
brain tumors with regard to IFN-γ response to full-length mesothelin and MPF with IL-2, IL-
15 and IL-21 conditioning. 
 
After confirming that patients with brain cancer can mount measurable cellular immune 
responses to the mesothelin precursor, we 
wanted to ascertain which epitopes within 
the mesothelin protein evoke the strongest 
IFN-γ response by T cells. Briefly we used a 
pool of 42 chemically synthesized peptides 
spanning the full-length mesothelin. The 
first 18 peptides comprise the MPF 
component, while the following 24 peptides 
constitute the mature mesothelin domain. 
We plotted the absolute values for IFN-γ 
production per patient, as well as the 
percentage of normalised average response. 
(Figure 10) TILs generated from GBM 
patients, expanded with cocktail IL-2/15/21, were also evaluated for their response to 
mesothelin peptides and we observed anti-mesothelin reactive TILs defined by ICS (0.41% of 
IFN-γ and 0.71% of TNF-α in CD3+ T -cells ) 
 
To the best of our knowledge, mesothelin has not been studied in the context of malignant 
brain cancer in humans. Using immunofluorescence microscopy, we could visualize that the 
mesothelin protein is overexpressed in human GBM tissue samples. Furthermore, our 
immunological data suggests that T cells from patients with malignant primary glioma (i.e. 
GBM) can strongly recognize and respond to cell surface-bound mesothelin (GPI-anchored 
component) via cytokine production (IFN-γ and TNF-α). T cells from patients with GBM are 
able to expand strongly in the presence of conditioning of growth medium with IL-2/IL-
15/IL-21 to the mesothelin peptide pool. This also applies to TILs from patients with GBM or 
pancreatic cancer, which are usually in contact with antigen-expressing cells in the tumor 
microenvironment [161]. 
MPF 
Mesothelin 
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3.4 Survivin peptide-specific cellular immune responses and cytokine 
networks predict the improved survival of patients with glioblastoma 
multiforme (Paper V) 
Central nervous system (CNS) cancers exhibit a very poor prognosis in patients, although 
they are significantly less frequent than other solid tumors i.e. lung cancer, melanoma, 
pancreatic cancer etc. [162]. The most common and aggressive clinical manifestation of 
glioma is GBM, which presents a 5-year survival less than 4% [162] , compared to the other 
primary gliomas ( WHO grade II and III), which exhit a 5-year survival rate of at least 50%. 
Patients (n=205) with the following diagnoses of malignant glioma were selected to 
participate in the study: glioblastoma multiforme (GBM, WHO grade IV CNS tumor, n=145) 
or non-GBM (n=60), comprising patients with astrocytoma, oligodendroglioma or not 
otherwise specified (NOS) categories, which may include oligoastrocytoma or anaplastic 
oligoastrocytoma (WHO grade II-III CNS tumors) [18]. Venous blood for laboratory studies 
was drawn from the participating patients for performance of the whole blood assay (WBA) 
and serum collection on the day of the surgery and prior to initiation of radio- and 
chemotherapy. Survival analysis in this paper focused on GBM and non-GBM cases that 
served as controls. 
 
The univariate analysis (The Kaplan-Meier (K-M) survival analysis) with log-rank test was 
performed by comparing single parameters (demographic, clinical, immunological and 
antigen-specific immune response) with the overall survival of patients with GBM. 
Demographic and clinical factors found in univariate analysis include: age of patients 
(p=0.0439), tumor recurrence (p=0.0397), Karnofsky Performance Status (KPS) of patients 
(p=0.0258), recursive partitioning analysis (RPA) before surgery (p=0.0435), radiotherapy 
(p<0.0001) and chemotherapy (p<0.0001). 
 
We found serum IL-4, IL-5 and IL-6 levels are significantly related between each two based 
on spearman correlation analysis (IL-4 vs IL-5, IL-5 vs IL-6 or IL-4 vs IL-6), similar to 
serum IFN-γ, TNF-α and IL-17A. When analyzing patients OS, we found that the entire set 
of IL-4, IL-5 and IL-6 as a pattern, i.e. either all three cytokines present or all absent (‘all’ or 
‘none’) correlated with a better survival profile (p=0.0022) among the patients compared to 
only a ‘partial’ combination (e.g. IL-4 and IL-5 are detectable but no IL-6, or IL-5 is 
detectable but no IL-4 and IL-6). The scenario is similar for IFN-γ/TNF-α/IL-17A levels in 
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serum; patients with all of the cytokines or none of cytokines tend to exhibit an improved 
survival pattern (p=0.0235). (Figure 11)  
 
Figure 11. Serum cytokine pattern related with patients OS 
 
We also measured antigen specific IFN-γ responses in peripheral blood from patients with 
GBM incubated with antigens (peptide mixes or single peptide): i.e. CMV pp65, EBV 
EBNA-1 and EBNA-3a, NY-ESO-1, survivin, mesothelin, EGFRvIII, survivin peptide 97-
111 (TLGEFLKLDRERAKN), NY-ESO-180-94 (ARGPESRLLEFYLA) in three conditions 
(no cytokine, IL-2/15/21 or IL-2/7) and correlated the cytokine production with the patients 
OS. Factors which showed significant relation with OS included: IFN-γ responses against 
CMV Pp65, EBNA-1, EBNA-3a and survivin97-111 cultured with IL-2/15/21. No single 
factor was observed with significance in condition to ‘no cytokine’ or ‘IL-2/7’. 
 
The single factors we mentioned above (i.e. demographic, clinical, immunological and 
antigen-specific immune response) were significantly correlated with patients’ OS in the 
univariate analysis (with a P<0.05 as cut-off), those parameters could be recruited into a Cox 
Proportional hazards model (forward and backward stepwise analysis) for multivariate 
analysis, results are showed in Table 3. Based on the COX hazards analysis, we identified the 
factors related with patients OS are: i). clinical parameters (chemotherapy and radiotherapy), 
ii). immunological parameters (serum IL-4/5/6 pattern and serum IFN-γ/TNF-α/IL-17A 
pattern) ,iii). antigen-specific immune response to survivin 97-111 and EBNA-1. 
 
Stepwise(COX) HR P 95% CI 
Radiotherapy 0,3368 <0.0001 0,20435 0,55502 
Chemotherapy 0,7143 0,028 0,52857 0,96521 
EBNA1 1,6397 0,051 0,99820 2,69339 
Survivin97-111  2,0756 0,024 1,09916 3,91960 
IL4/5/6 1,7851 0,052 0,99582 3,19990 
IFN-γ/TNF-α/IL-17A 2,2645 0,003 1,33067 3,85354 
 
Table 3. COX analysis confirmed single factors to predict survival of patients with GBM  
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4 CONCLUSION   
 
 ‘Classic’ TAAs such as NY-ESO-1, survivin and mesothelin are expressed in glioma 
tumor lesions.  
 
 Autologous tumor cells, tumor- or viral- antigens (NY-ESO-1, survivin, mesothelin or 
CMV Pp65) specific T cells either from peripheral blood or tumor tissues could be 
successfully expanded (large scale) within 4 weeks in IL-2/IL-15 and IL-21 showing 
a Th1-cytokine production pattern. These antigen-specific T-cells exhibit cytotoxicity 
and/or cytokine production and represent an attractive profile for cellular 
immunotherapy.  
 We found that serum cytokines like IL-4, IL-5, IL-6 in a combinational pattern and 
immunoreaction to survivin 97-111 or EBNA-1 could be employed as predictor of 
prognosis for patients with GBM. Survivin91-111 could serve as a target for ACT for 
patients with glioma.  
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5 FUTURE WORK 
 
  We could establish a number of NY-ESO-1 and survivin specific T cell line(s) from 
PBMCs from patients with glioblastoma. These T-cells produced IFNγ and TNFα 
after expansion. According to our unpublished data, we were able to expand T-cells 
from 35 million to 2.2 billion within 3 weeks, a cell number which would meet the 
scale for clinical therapy requirement. We will focus to streamline the T-cell 
expansion process and to test whether sufficient numbers of T-cells could be 
expanded for future biological therapy, including the preferentially expansion of NY-
ESO-1 or survivin directed T-cells.  
 
 We could reliably expand TILs from brain tumor and pancreatic cancer tissues with 
strong reactivity and specificity to autologous tumor cells, the TILs showed potent 
cytokine production and cytotoxicity. We will focus on the further characterization of 
the TILs, including functional and phenotypical analysis and subsequent TCR 
sequencing in order to develop fast and effective T cells products which could be for 
potential products for T cell therapy.  
   
 We had shown that the ex vivo expansion of TILs from patients with glioma and 
pancreatic cancer leads to strong expansion of certain TCR Vβ families, defined by 
flow cytometry. We postulate that these expanded TCR Vβ families are directed 
against the patient’s own tumor cells. We plan therefore to sort these cells and 
perform TCR sequence analysis by PCR. Specificity could be tested for selected T-
cell lines by TCR transfer; a similar approach would be used for the NY-ESO-1 
tetramer sorted T cells in order to obtain a broader repertoire of anti-NY-ESO-1 
directed TCRs that could be used for biological therapy. 
 
 We plan to purify and expand mesothelin epitope specific cells from PBMCs and 
TILs of patients with glioma via mesothelin dextramer sorting for further TCR 
sequencing and TCR transfer.  
 
 We plan to carry out mesothelin immunohistochemistry on glioma samples with 
different histology of glioma (grade I-IV) to study mesothelin expression in glioma 
with GBM histology. 
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 We plan to purify survivin 97-111 epitope directed T cells for TCR sequencing which 
could be useful for future treatment due to the correlation between survivin 97-111 
immune responses and patient’s survival. 
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